ORIDIVUS LLC
Oral wound healing supplement
- Sector
- UNCERTAIN
- Total capital
- $361K
- Federal grants
- $361K
- 2 awards · 2024–2025
- 2.0× sector median 1 award
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 1 pending · first 2025
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Innovative oral regenerative therapy leveraging immunoregenerative mechanisms.$55K
- Federal grantHealth and Human S · Phase I · Innovative oral regenerative therapy leveraging immunoregenerative mechanisms.$306K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 2- PendingUniaxially-aligned Nanofiber Scaffolds And Methods For Producing And Using SameUSPTOApplication 19097351
- GrantedUniaxially-aligned Nanofiber Scaffolds And Methods For Producing And Using SameUSPTOUS 12,263,277
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .